INBX - Inhibrx, Inc. Stock Price, Fair Value and News

34.04USD-0.25 (-0.73%)Market Closed

Market Summary

USD34.04-0.25

Market Closed

-0.73%

INBX Stock Price

View Fullscreen

INBX RSI Chart

INBX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-6.58

Price/Sales (Trailing)

149.68

EV/EBITDA

-6.34

Price/Free Cashflow

-8.03

INBX Price/Sales (Trailing)

INBX Profitability

EBT Margin

-2261.63%

Return on Equity

-2.3K%

Return on Assets

-93.96%

Free Cashflow Yield

-12.45%

INBX Fundamentals

INBX Revenue

Revenue (TTM)

11.9M

INBX Earnings

Earnings (TTM)

-271.2M

Earnings Growth (Yr)

-60.91%

Earnings Growth (Qtr)

15.91%

Breaking Down INBX Revenue

Last 7 days

-0.8%

Last 30 days

-2.7%

Last 90 days

-8.6%

Trailing 12 Months

37.7%

How does INBX drawdown profile look like?

INBX Financial Health

Current Ratio

3.82

INBX Investor Care

Shares Dilution (1Y)

20.14%

Diluted EPS (TTM)

-5.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.5M	7.0M	9.5M	11.9M
2022	7.3M	5.5M	3.8M	2.1M
2021	12.9M	10.5M	7.2M	7.2M
2020	13.1M	13.0M	13.0M	12.9M
2019	0	0	0	13.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Inhibrx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 28, 2023	viking global investors lp	bought	9,899,980	19.35	511,627	-
Mar 01, 2023	eckelman brendan p.	sold	-968,231	24.2058	-40,000	chief scientific officer
Feb 28, 2023	lappe mark	sold	-1,501	25.0208	-60.00	chief executive officer
Feb 02, 2023	eckelman brendan p.	sold	-286,355	25.4537	-11,250	chief scientific officer
Feb 01, 2023	eckelman brendan p.	sold	-710,856	24.7254	-28,750	chief scientific officer
Jan 24, 2023	lappe mark	sold	-111,478	25.7159	-4,335	chief executive officer
Jan 23, 2023	lappe mark	sold	-549,364	25.3572	-21,665	chief executive officer
Jan 23, 2023	kayyem jon faiz	sold	-239,999	25.2631	-9,500	-
Jan 04, 2023	eckelman brendan p.	sold	-166,829	23.4805	-7,105	chief scientific officer
Jan 03, 2023	eckelman brendan p.	sold	-781,770	23.7656	-32,895	chief scientific officer

Which funds bought or sold INBX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CREDIT SUISSE AG/	reduced	-5.98	-101,303	648,893	-%
May 10, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-481,308	-	-%
May 10, 2024	Covestor Ltd	unchanged	-	-	-	-%
May 10, 2024	CITIGROUP INC	added	641	9,884,100	11,582,300	0.01%
May 10, 2024	Campbell & CO Investment Adviser LLC	sold off	-100	-893,608	-	-%
May 10, 2024	JPMORGAN CHASE & CO	added	41.22	585,842	2,543,830	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-0.69	-6,147,320	65,077,000	-%
May 10, 2024	BlackRock Inc.	added	1.33	-6,995,930	96,199,600	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	32,932	32,932	-%
May 10, 2024	HCR Wealth Advisors	unchanged	-	-19,152	220,248	0.03%

Are Funds Buying or Selling INBX?

Are funds buying INBX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INBX

No. of Funds

Unveiling Inhibrx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eckelman brendan p.	4.3%	2,035,553	SC 13G/A
Feb 14, 2024	kayyem jon faiz	7.0%	3,308,123	SC 13G/A
Feb 14, 2024	lappe mark	5.2%	2,486,192	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	4,724,352	SC 13G/A
Feb 14, 2024	perceptive advisors llc	9.9%	4,776,306	SC 13G/A
Feb 14, 2024	viking global investors lp	15.1%	7,150,826	SC 13G/A
Jan 29, 2024	blackrock inc.	5.7%	2,715,672	SC 13G/A
Jan 23, 2024	state street corp	3.46%	1,635,726	SC 13G/A
Mar 09, 2023	inhibrx, inc.	5.8%	2,512,252	SC 13G/A
Mar 09, 2023	inhibrx, inc.	4.9%	2,155,553	SC 13G/A

Recent SEC filings of Inhibrx, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 08, 2024	4	Insider Trading
May 08, 2024	8-K	Current Report
May 06, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	DEFM14A	DEFM14A
Mar 28, 2024	4	Insider Trading
Mar 26, 2024	144	Notice of Insider Sale Intent
Mar 22, 2024	144	Notice of Insider Sale Intent
Mar 22, 2024	4	Insider Trading

Peers (Alternatives to Inhibrx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Inhibrx, Inc. News

Latest updates

Inhibrx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-	-	-	-	2,414,000	1,285,000	156,000	278,000	603,500	929,000	2,856,000	2,532,000	954,000	889,000	2,776,000	5,901,000	3,339,000	872,000	1,045,500	1,219,000
Operating Expenses	-17.9%	73,825,000	89,923,000	45,946,000	41,369,000	43,783,000	35,774,000	30,281,000	35,308,000	29,946,000	22,260,000	21,333,000	20,755,000	19,447,000	19,883,000	21,459,000	20,506,000	18,483,000	-	14,266,000
S&GA Expenses	-100.0%	-	7,832,000	7,889,000	7,263,000	6,397,000	5,323,000	5,347,000	5,402,000	5,051,000	3,645,000	2,848,000	2,853,000	3,009,000	2,215,000	1,622,000	1,532,000	1,467,000	-	1,481,000
R&D Expenses	-22.2%	63,851,000	82,091,000	38,057,000	34,106,000	37,386,000	30,451,000	24,934,000	29,906,000	24,895,000	18,615,000	18,485,000	17,902,000	16,438,000	17,668,000	19,837,000	18,974,000	17,016,000	-	12,785,000
EBITDA Margin	-14.0%	-20.27	-17.77	-17.49	-21.29	-31.71	-63.12	-30.10	-18.59	-12.07	-10.60	-10.45	-7.10	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	6,672,000	6,276,000	5,256,000	3,859,000	2,473,000	1,502,000	1,888,000	679,000	725,000	597,000	332,000	133,000	-	39,000	-	-
Income Taxes	100.0%	-	-4,000	2,000	5,000	-	-1,000	-	4,000	-	-	-	-	2,000	3,000	-	-	-	-	900,000
Earnings Before Taxes	14.4%	-78,710,000	-91,974,000	-51,787,000	-47,047,000	-48,916,000	-40,916,000	-35,325,000	-37,728,000	-31,254,000	-21,189,000	-20,580,000	-20,710,000	-19,287,000	-17,646,000	-20,010,000	-17,885,000	-20,093,000	-	-19,263,000
EBT Margin	-12.4%	-22.62	-20.12	-19.95	-24.62	-35.92	-70.02	-32.97	-20.00	-12.89	-11.31	-10.94	-7.38	-	-	-	-	-	-	-
Net Income	15.9%	-78,710,000	-93,604,000	-51,789,000	-47,052,000	-48,916,000	-40,915,000	-35,325,000	-37,732,000	-31,254,000	-21,189,000	-20,580,000	-20,710,000	-19,289,000	-17,649,000	-20,497,000	-17,885,000	-20,093,000	-16,305,000	-20,163,000
Net Income Margin	-12.3%	-22.75	-20.25	-19.95	-24.62	-35.92	-70.02	-32.97	-20.00	-12.89	-11.31	-10.94	-7.43	-	-	-	-	-	-	-
Free Cashflow	-6.5%	-64,169,000	-60,263,000	-55,056,000	-42,616,000	-39,967,000	-30,867,000	-30,818,000	-27,244,000	-27,058,000	-22,887,000	-13,844,000	-22,794,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-6.3%	289	308	373	213	254	291	165	193	161	150	129	142	125	144	144	26.00
Current Assets	-7.0%	275	295	363	203	244	280	154	182	150	139	119	131	113	132	132	16.00
Cash Equivalents	-9.2%	252	278	337	192	234	274	146	176	143	131	113	126	108	129	128	12.00
Net PPE	8.5%	7.00	6.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	4.8%	277	264	243	238	239	233	200	198	134	98.00	101	98.00	64.00	68.00	52.00	61.00
Current Liabilities	27.6%	72.00	56.00	36.00	31.00	33.00	28.00	25.00	24.00	20.00	22.00	25.00	22.00	28.00	31.00	35.00	21.00
LT Debt, Current	-	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00
Shareholder's Equity	-73.4%	12.00	44.00	130	-	15.00	58.00	-	-	27.00	52.00	28.00	44.00	61.00	75.00	92.00	-
Retained Earnings	-12.8%	-692	-613	-520	-468	-421	-372	-331	-296	-258	-227	-206	-185	-164	-145	-127	-69.25
Additional Paid-In Capital	7.1%	704	657	650	444	436	430	296	291	286	280	234	230	225	221	219	-24.32
Shares Outstanding	3.9%	49.00	47.00	47.00	44.00	44.00	44.00	39.00	39.00	39.00	39.00	38.00	38.00	-	-	-	-
Float	-	-	-	-	893	-	-	-	331	-	-	-	764	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-11.0%	-63,050	-56,821	-54,245	-42,299	-39,944	-30,600	-30,838	-26,922	-26,941	-22,620	-13,675	-22,380	-21,648	-15,389	-13,882	-11,309	-7,388	-	-
Share Based Compensation	-0.5%	6,397	6,427	6,530	6,253	5,636	5,355	4,691	5,296	5,108	4,183	3,493	3,951	3,421	1,373	1,303	1,259	1,088	-	-
Cashflow From Investing	67.5%	-1,119	-3,442	-811	-317	-23.00	-267	20.00	-322	-117	-267	-169	-359	-14.00	-612	-299	-362	-91.00	-	-
Cashflow From Financing	4403.3%	38,728	860	199,891	854	356	158,659	506	60,162	39,224	41,484	820	40,477	988	16,996	136,218	16,875	-3,633	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INBX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 0	$ 17
Operating expenses:
Research and development	63,851	37,386
General and administrative	9,974	6,397
Total operating expenses	73,825	43,783
Loss from operations	(73,825)	(43,766)
Other income (expense):
Interest expense	(8,130)	(7,563)
Interest income	3,304	2,483
Other expense, net	(59)	(70)
Total other expense	(4,885)	(5,150)
Loss before income tax expense	(78,710)	(48,916)
Provision for income taxes	0	0
Net loss	$ (78,710)	$ (48,916)
Net loss per share, basic (in dollars per share)	$ (1.44)	$ (1.12)
Net loss per share, diluted (in dollars per share)	$ (1.44)	$ (1.12)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic (in shares)	54,554	43,575
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted (in shares)	54,554	43,575
License fee revenue
Revenue:
Total revenue	$ 0	$ 17

INBX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 252,483	$ 277,924
Accounts receivable	171	171
Other receivables	2,867	607
Prepaid expenses and other current assets	19,017	16,656
Total current assets	274,538	295,358
Property and equipment, net	6,966	6,419
Operating right-of-use asset	2,487	2,952
Other non-current assets	4,586	3,164
Total assets	288,577	307,893
Current liabilities:
Accounts payable	14,792	10,954
Accrued expenses	51,329	43,295
Current portion of long-term debt, net of discount	3,632	0
Current portion of operating lease liability	2,117	2,063
Total current liabilities	71,870	56,312
Long-term debt, including debt discount and final payment fee	204,578	206,968
Non-current portion of operating lease liability	561	1,110
Total liabilities	277,009	264,390
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023.	0	0
Common stock, $0.0001 par value; 120,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 49,234,225 and 47,369,511 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	5	5
Additional paid-in-capital	704,007	657,232
Accumulated deficit	(692,444)	(613,734)
Total stockholders’ equity	11,568	43,503
Total liabilities and stockholders’ equity	$ 288,577	$ 307,893

About Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

CEO	Mr. Mark Paul Lappe
WEBSITE	https://inhibrx.com
INDUSTRY	Biotechnology
EMPLOYEES	132

Inhibrx, Inc. Frequently Asked Questions

What is the ticker symbol for Inhibrx, Inc.? What does INBX stand for in stocks?

INBX is the stock ticker symbol of Inhibrx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inhibrx, Inc. (INBX)?

As of Mon May 13 2024, market cap of Inhibrx, Inc. is 1.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers. The fair value of Inhibrx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inhibrx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INBX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inhibrx, Inc. a good stock to buy?

The fair value guage provides a quick view whether INBX is over valued or under valued. Whether Inhibrx, Inc. is cheap or expensive depends on the assumptions which impact Inhibrx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INBX.

What is Inhibrx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, INBX's PE ratio (Price to Earnings) is -6.58 and Price to Sales (PS) ratio is 149.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INBX PE ratio will change depending on the future growth rate expectations of investors.